116 related articles for article (PubMed ID: 8886909)
1. The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors.
Uozumi J; Koikawa Y; Yasumasu T; Tokuda N; Kumazawa J
Int J Urol; 1996 Sep; 3(5):343-7. PubMed ID: 8886909
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer.
Rojanasthien N; Kumsorn B; Atikachai B; Leotrakul S; Thongprasert S
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):121-5. PubMed ID: 11396752
[TBL] [Abstract][Full Text] [Related]
3. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
5. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
6. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
7. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity in rats].
Koikawa Y; Uozumi J; Yasumasu T; Ueda T; Kumazawa J
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1363-7. PubMed ID: 8346934
[TBL] [Abstract][Full Text] [Related]
8. Methylprednisolone reduces the nephrotoxicity caused by cisplatin.
Uozumi J; Koikawa Y; Ueda T
J Pharmacobiodyn; 1992 Dec; 15(12):693-7. PubMed ID: 1296980
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
[TBL] [Abstract][Full Text] [Related]
10. The effect of methylprednisolone on platinum kinetics and urinary enzyme excretion following intravenous cisplatin in vivo and on the growth inhibition of LLC-PK1 cells by cisplatin in vitro.
Uozumi J; Koikawa Y; Yasumasu T; Tokuda N; Ueda T; Kumazawa J
Res Exp Med (Berl); 1996; 196(4):211-7. PubMed ID: 8903096
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
12. [Why use chemotherapy in cancer of the bladder? What are the initial limitations].
Maraninchi D; Viens P
Ann Urol (Paris); 1994; 28(6-7):334-7. PubMed ID: 7534457
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Goren MP; Wright RK; Horowitz ME; Meyer WH
Cancer; 1986 Dec; 58(12):2617-21. PubMed ID: 2877729
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.
Witjes JA; Wullink M; Oosterhof GO; de Mulder P
Eur Urol; 1997; 31(4):414-9. PubMed ID: 9187900
[TBL] [Abstract][Full Text] [Related]
15. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
Logothetis CJ; Finn LD; Smith T; Kilbourn RG; Ellerhorst JA; Zukiwski AA; Sella A; Tu SM; Amato RJ
J Clin Oncol; 1995 Sep; 13(9):2272-7. PubMed ID: 7666085
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of verapamil on cis-platinum and carboplatinum nephrotoxicity in dehydrated and normohydrated rats.
Haragsim L; Zima T
Biochem Int; 1992 Oct; 28(2):273-6. PubMed ID: 1360799
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
[TBL] [Abstract][Full Text] [Related]
18. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
19. Effect of N-N'-diphenyl-p-phenylenediamine pretreatment on urinary enzyme excretion in cisplatin nephrotoxicity in rats.
Gemba M; Fukuishi N; Nakano S
Jpn J Pharmacol; 1988 Jan; 46(1):90-2. PubMed ID: 2896807
[TBL] [Abstract][Full Text] [Related]
20. [Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].
Heidenreich A; Marx FJ; Peters HJ
Urologe A; 1999 Nov; 38(6):586-91. PubMed ID: 10591805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
